Fatty Acid Synthase (FASN) Inhibitors Market, Global Outlook and Forecast 2023-2030
Fatty Acid Synthase (FASN) Antibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific peptide. FASN is a key enzyme involved in the production of saturated fatty acids in the liver and other organs and is the only enzyme in the human body capable of converting metabolized sugars into palmitate. Palmitate is a saturated fatty acid that serves as a building block for longer chain, polyunsaturated fatty acids and can directly interact with other proteins to sustain normal cell signaling and metabolic function. The overproduction of palmitate is a critical driver of cellular metabolic dysfunction that can drive development or progression of several different diseases. In patients with NASH, increased FASN-mediated palmitate synthesis in the liver is the source of three key drivers of the disease: excess accumulation of liver fat, inflammation and fibrosis. If left untreated, these can lead to cirrhosis of the liver, liver cancer and/or liver transplantation.
This report aims to provide a comprehensive presentation of the global market for Fatty Acid Synthase (FASN) Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Fatty Acid Synthase (FASN) Inhibitors. This report contains market size and forecasts of Fatty Acid Synthase (FASN) Inhibitors in global, including the following market information:
Global Fatty Acid Synthase (FASN) Inhibitors Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Fatty Acid Synthase (FASN) Inhibitors market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Powder Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Fatty Acid Synthase (FASN) Inhibitors include Merck, Abcam, Tocris Bioscience, MedChemExpress, Sagimet Biosciences, R?D Systems and Santa Cruz Biotechnology, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We has surveyed the Fatty Acid Synthase (FASN) Inhibitors companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Fatty Acid Synthase (FASN) Inhibitors Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Fatty Acid Synthase (FASN) Inhibitors Market Segment Percentages, by Type, 2022 (%)
Powder
Solid
Global Fatty Acid Synthase (FASN) Inhibitors Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Fatty Acid Synthase (FASN) Inhibitors Market Segment Percentages, by Application, 2022 (%)
Medical
Research Laboratories
Other
Global Fatty Acid Synthase (FASN) Inhibitors Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Fatty Acid Synthase (FASN) Inhibitors Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Fatty Acid Synthase (FASN) Inhibitors revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Fatty Acid Synthase (FASN) Inhibitors revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
Abcam
Tocris Bioscience
MedChemExpress
Sagimet Biosciences
R?D Systems
Santa Cruz Biotechnology
Outline of Major Chapters:
Chapter 1: Introduces the definition of Fatty Acid Synthase (FASN) Inhibitors, market overview.
Chapter 2: Global Fatty Acid Synthase (FASN) Inhibitors market size in revenue.
Chapter 3: Detailed analysis of Fatty Acid Synthase (FASN) Inhibitors company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Fatty Acid Synthase (FASN) Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
